Related Experiment Video
Updated: Jun 5, 2026

Detection of Protein S-Acylation using Acyl-Resin Assisted Capture
Published on: April 10, 2020
Deactivation of sodium tetradecyl sulphate injection by blood proteins
1STD Pharmaceutical Products Ltd, Plough Lane, Hereford HR4 0EL, United Kingdom. mikewatkins@stdpharm.co.uk
Objectives:
The aim of this work was to quantify the volume of blood required to deactivate 1 ml of 3% sodium tetradecyl sulphate (STS).
Design:
A series of experiments were performed where the concentration of STS remaining in a stock solution was measured after adding increasing volumes of blood protein solutions.
Materials And Methods:
Increasing volumes of bovine serum albumin, bovine erythrocytes and a mixture of both was added to a stock solution of STS. The BP manual titration method was used to measure the assay of the remaining STS.
Results:
The method was reproducible and increasing volumes of blood protein lowered the STS concentration in a linear fashion. Approximately 2 ml of a 4% blood protein solution deactivates 1 ml of 3% STS, which means approximately 0.5 ml of whole blood will deactivate 1 ml of 3% STS.
Conclusions:
Sodium tetradecyl sulphate injection is deactivated by a relatively small volume of blood. The practical implication is that changes in technique to reduce the blood volume in larger veins and to introduce fresh aliquots of sclerosant along the length of the vein could improve the efficacy of sclerotherapy.
More Related Videos
11:04Unraveling the Role of Discrete Areas of the Rat Brain in the Regulation of Ovulation through Reversible Inactivation by Tetrodotoxin Microinjections
Published on: September 3, 2020
11:25Targeting Cysteine Thiols for in Vitro Site-specific Glycosylation of Recombinant Proteins
Published on: October 4, 2017
Related Concept Videos
Desensitization and Tachyphylaxis
Several...
Hypersensitivity Reactions: Cytolytic Reactions
Drug Binding to Blood Components
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...
Drug Toxicity: Allergic Reactions
Drug Distribution: Plasma Protein Binding
Depolarizing Blockers: Pharmocokinetics